Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GQPHW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
hRS7 ATAC 2
|
|||||
| Synonyms |
hRS7 ATAC 2
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma Research GmbH.; Heidelberg Pharma AG.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.05
|
|||||
| Structure |
|
|||||
| Antibody Name |
hRS7
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Alpha-amanitin
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Maleimide-noncleavable-C6-linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation via engineered cysteine residues at position D265 (DC) in the Fc part of the antibody
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.1 nM | Moderate TROP2 expression (TROP2++) | ||
| Method Description |
Cells were seeded at a density of 2 × 103 cells/well in 90 uL of the respective culture medium. On the following day, cells were exposed to ATACs and incubated at 37°C and 5% CO2 with serial dilutions from 1 × 10-7 mol/L to 1.28 × 10-12 mol/L of the ATACs for 96 hours. Cell proliferation was assessed by the BrdU chemiluminescent ELISA assay (Roche; Sigma-Aldrich/Merck, Cat. # 1669915001), according to the manufacturer's instructions. Luminescence signal intensities were measured directly in a microplate reader (BMG CLARIOstar). Triplicate wells were used for each treatment, and viability was normalized to untreated cells. Error was calculated as the SEM of three independent experiments.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-2 cells | CVCL_0026 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.2 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Cells were seeded at a density of 2 × 103 cells/well in 90 uL of the respective culture medium. On the following day, cells were exposed to ATACs and incubated at 37°C and 5% CO2 with serial dilutions from 1 × 10-7 mol/L to 1.28 × 10-12 mol/L of the ATACs for 96 hours. Cell proliferation was assessed by the BrdU chemiluminescent ELISA assay (Roche; Sigma-Aldrich/Merck, Cat. # 1669915001), according to the manufacturer's instructions. Luminescence signal intensities were measured directly in a microplate reader (BMG CLARIOstar). Triplicate wells were used for each treatment, and viability was normalized to untreated cells. Error was calculated as the SEM of three independent experiments.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.2 nM | High TROP2 expression (TROP2 +++) | ||
| Method Description |
Cells were seeded at a density of 2 × 103 cells/well in 90 uL of the respective culture medium. On the following day, cells were exposed to ATACs and incubated at 37°C and 5% CO2 with serial dilutions from 1 × 10-7 mol/L to 1.28 × 10-12 mol/L of the ATACs for 96 hours. Cell proliferation was assessed by the BrdU chemiluminescent ELISA assay (Roche; Sigma-Aldrich/Merck, Cat. # 1669915001), according to the manufacturer's instructions. Luminescence signal intensities were measured directly in a microplate reader (BMG CLARIOstar). Triplicate wells were used for each treatment, and viability was normalized to untreated cells. Error was calculated as the SEM of three independent experiments.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 138 nM | Moderate TROP2 expression (TROP2++) | ||
| Method Description |
Cells were seeded at a density of 2 × 103 cells/well in 90 uL of the respective culture medium. On the following day, cells were exposed to ATACs and incubated at 37°C and 5% CO2 with serial dilutions from 1 × 10-7 mol/L to 1.28 × 10-12 mol/L of the ATACs for 96 hours. Cell proliferation was assessed by the BrdU chemiluminescent ELISA assay (Roche; Sigma-Aldrich/Merck, Cat. # 1669915001), according to the manufacturer's instructions. Luminescence signal intensities were measured directly in a microplate reader (BMG CLARIOstar). Triplicate wells were used for each treatment, and viability was normalized to untreated cells. Error was calculated as the SEM of three independent experiments.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-2 cells | CVCL_0026 | ||
References